Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome
Open Access
- 20 September 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (18) , 6906
Abstract
Down syndrome (DS), the most common cause of intellectual disability of genetic origin, is characterized by alterations in central nervous system morphology and function that appear from early prenatal stages. However, by the fourth decade of life, all individuals with DS develop neuropathology identical to that found in sporadic Alzheimer’s disease (AD), including the development of amyloid plaques and neurofibrillary tangles due to hyperphosphorylation of tau protein, loss of neurons and synapses, reduced neurogenesis, enhanced oxidative stress, and mitochondrial dysfunction and neuroinflammation. It has been proposed that DS could be a useful model for studying the etiopathology of AD and to search for therapeutic targets. There is increasing evidence that the neuropathological events associated with AD are interrelated and that many of them not only are implicated in the onset of this pathology but are also a consequence of other alterations. Thus, a feedback mechanism exists between them. In this review, we summarize the signalling pathways implicated in each of the main neuropathological aspects of AD in individuals with and without DS as well as the interrelation of these pathways.Keywords
Funding Information
- Instititute of Research Valdecilla (IDIVAL) (NVAL 19/23)
This publication has 391 references indexed in Scilit:
- Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesisJournal of Neuroinflammation, 2013
- Role of Neuroinflammation in Adult Neurogenesis and Alzheimer Disease: Therapeutic ApproachesMediators of Inflammation, 2013
- Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndromeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Antioxidants in Down syndromeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndromeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Neurological phenotypes for Down syndrome across the life span2012
- Positron Emission Tomography and Neuropathologic Estimates of Fibrillar Amyloid-β in a Patient With Down Syndrome and Alzheimer DiseaseArchives of Neurology, 2011
- Why Pleiotropic Interventions are Needed for Alzheimer's DiseaseMolecular Neurobiology, 2010
- The effect of mGluR2 activation on signal transduction pathways and neuronal cell survivalBrain Research, 2009
- Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down SyndromeInternational Journal of Geriatric Psychiatry, 2008